Beslutninger på Vestjysk Bank A/S’ ordinære generalforsamling den 9. marts 2023
Nasdaq Copenhagen A/S
I dag, den 9. marts 2023, afholdte banken ordinær generalforsamling med følgende dagsorden som tidligere offentliggjort:
- Bestyrelsens mundtlige beretning om Bankens virksomhed i det forløbne år
- Fremlæggelse af revideret årsrapport til godkendelse
- Beslutning om anvendelse af overskud eller dækning af underskud i henhold til den godkendte årsrapport
- Fremlæggelse af vederlagsrapport til vejledende afstemning
- Godkendelse af vederlag til bestyrelsen for det indeværende regnskabsår
- Valg af medlemmer til bestyrelsen, herunder formand og næstformand
- Valg af revisor
- Forslag fra bestyrelsen eller aktionærer
8.a. Bemyndigelse til bestyrelsen til at erhverve egne aktier
8.b Fornyelse af bestyrelsens bemyndigelse til at forhøje aktiekapitalen uden fortegningsret for eksisterende aktionærer (vedtægternes punkt 10.10)
8.c Fornyelse af bestyrelsens bemyndigelse til at forhøje aktiekapitalen med fortegningsret for eksisterende aktionærer (vedtægternes punkt 10.11)
8.d Ændring af bestyrelsens sammensætning (vedtægternes punkt 10.1)
8.e Fjernelse af binavn (vedtægternes punkt 1.2)
8.f Præcisering af vedtægternes punkt 9.7
8.g Bemyndigelse til dirigenten
- Eventuelt
Bestyrelsens beretning blev indledningsvist taget til efterretning og den reviderede årsrapport for 2022 samt bestyrelsens forslag om anvendelse af overskud i henhold til den godkendte årsrapport blev herefter vedtaget. Årets resultat anvendes derfor således:
- Udbetaling af udbytte på DKK 0,110061 pr. aktie, svarende til ca. 135,8 mio. kroner.
- Overførsel af DKK 20.460.000 til indehavere af hybrid kapital.
- Henlæggelse af DKK 387.108.000 til egenkapitalen.
Ved vejledende afstemning godkendte generalforsamlingen vederlagsrapporten for 2022, og herefter blev forslaget om vederlag til medlemmerne af bestyrelsen for det indeværende regnskabsår vedtaget. Endelig blev forslaget om vederlag for bæredygtighedsudvalget for regnskabsåret 2022 med tilbagevirkende kraft vedtaget.
De generalforsamlingsvalgte bestyrelsesmedlemmer vælges for ét år ad gangen, hvorfor valgperioden for sådanne bestyrelsesmedlemmer udløb på den ordinære generalforsamling. Kim Rønnow Duus, Gert Rinaldo Jonassen, Anna Bolette van Ingen Bro, Hanne Træholt Odegaard, Bent Ejnar Juul Simonsen, Jan Nordstrøm, og Lars Langhoff blev alle genvalgt. Kim Rønnow Duus blev genvalgt som formand for bestyrelsen. Derudover blev Gert Rinaldo Jonassen genvalgt som næstformand for bestyrelsen.
EY Godkendt Revisionspartnerselskab blev genvalgt som revisor for banken.
Forslagene i punkt 8.a. til og med 8.g. som fremsat af bestyrelsen blev alle vedtaget af generalforsamlingen som fremsat i indkaldelsen med den fuldstændige dagsorden den 9. februar 2023.
Dirigenten blev bemyndiget – med substitutionsret – til at anmelde det vedtagne til Erhvervsstyrelsen samt foretage de ændringer og tilføjelser heri, som måtte blive krævet af Erhvervsstyrelsen eller andre offentlige myndigheder.
En generalforsamlingsprotokol vil blive gjort tilgængelig på Vestjysk Banks hjemmeside www.vestjyskbank.dk senest 2 uger fra dags dato.
Vestjysk Bank A/S
Bestyrelsen
Vestjysk Bank A/S
Industrivej Syd 13C
7400 Herning
Telefon 96 63 20 00
CVR-nr. 34 63 13 28
www.vestjyskbank.dk
For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
Grant of Restricted Stock Units and Warrants to Employees in Genmab8.6.2023 23:22:17 CEST | Press release
Company Announcement COPENHAGEN, Denmark; June 8, 2023 –Genmab A/S (Nasdaq:GMAB) announced todaythat the Board decided to grant 7,825 restricted stock units and 8,106 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 2,688. The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the Board of Directors. Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Governance > Compensation > Restricted Stock Units. The exercise price fo
Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants8.6.2023 23:19:00 CEST | Press release
FDA Advisory Committee unanimously recommendsnirsevimab as first immunization against RSV disease forall infants Nirsevimab would be the first immunization specifically designed to protect all infants through their first RSV season, if approvedAcross all clinical trials, a single dose of nirsevimab delivered high, consistent and sustained efficacy and favorable safety against RSV diseaseThe FDA has indicated it will work to expedite its review; Sanofi remains committed to delivering nirsevimab in time for the 2023-2024 RSV season Paris, June 8, 2023. The U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously 21 to 0 that Sanofi and AstraZeneca’s nirsevimab has a favorable benefit risk profile for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season. The Committee also voted 19 to 2 in support of nirsevimab’s favorable benefit ris
DBV Technologies to Participate in Upcoming EAACI Congress 20238.6.2023 22:30:00 CEST | Press release
Montrouge, France, June 8, 2023 DBV Technologies to Participate in Upcoming EAACI Congress 2023 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 9 – 11, 2023, in Hamburg, Germany. DBV will present three posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. Data to be presented during the scientific sessions will describe the current burden of peanut allergy and treatment management strategies for children in the U.K. DBV will also present data from its completed EPITOPE Phase 3 study assessing the efficacy and safety of epicutaneous immunotherapy (EPIT) using Viaskin Peanut™ in toddlers aged 1-3 years with or without concomitant asthma. The toddler age-group represents the age range in which many peanut-allergic children are diagnosed, yet there are currently n
GOGL - Transactions made under the buy-back program8.6.2023 22:30:00 CEST | Press release
Reference is made to the stock announcement on October 4, 2022, where Golden Ocean Group Limited (OSE/NASDAQ: GOGL) announced the commencement of its share buy-back program of maximum USD 100 million to purchase up to an aggregate of 10,000,000 of the company's common shares in a 12-month period from the announcement. Golden Ocean Group Limited (“GOGL” or the “Company”) announces that the Company has during the week ending Friday June 2, 2023, purchased 25,343 of the Company’s own common stocks. 343 of the shares have been bought on the Oslo Stock Exchange at an average price of NOK 80.00 per share and 25,000 of the shares have been bought on Nasdaq at an average price of USD 7.19 per share. Following the completion of the above transactions, GOGL owns a total of 952,428 of own shares, corresponding to 0.47% of the Company’s share capital. An overview of all transactions made under the buy-back program that have been carried out during the above-mentioned date is attached to this repor
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants8.6.2023 22:00:00 CEST | Press release
Company announcement – No. 25 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, June 8, 2023– Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 36,006 divided into 36,006 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under several of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma’s incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand Pharma share at a prespecified price, the exercise price, in specific predefined time periods before expiration. For a more detailed description of Zealand Pharma’s warrant programs, see the company’s Articles of Association, which are